School of Natural Sciences Chemistry, University of Tasmania, Hobart, Australia.
School of Medicine, University of Tasmania, Hobart, Australia.
ChemMedChem. 2018 Sep 19;13(18):1873-1884. doi: 10.1002/cmdc.201800401. Epub 2018 Aug 16.
Platelet-activating factor (PAF) and its receptor (PAFr) have been implicated in a wide range of diseases and disorders that originate from the activation of inflammatory pathways. Although the exact structure of the binding site on the PAFr remains unknown, the PAFr is a well-established therapeutic target, and an array of structurally diverse PAFr antagonists have been identified. These include compounds that are structurally similar to the natural PAF ligand, synthetic heterocycles, complex polycyclic natural products, and various metal complexes. This review provides an update on more than 20 years of progress in this area. The development and synthesis of new PAFr antagonists, structure-activity relationship studies, the biological activity of these molecules, and their therapeutic potential are discussed.
血小板激活因子(PAF)及其受体(PAFr)参与了广泛的疾病和紊乱,这些疾病和紊乱起源于炎症途径的激活。尽管 PAFr 上结合位点的确切结构仍不清楚,但 PAFr 是一个成熟的治疗靶点,已经确定了一系列结构多样的 PAFr 拮抗剂。这些包括与天然 PAF 配体结构相似的化合物、合成杂环、复杂的多环天然产物和各种金属配合物。本综述提供了该领域 20 多年来的最新进展。讨论了新的 PAFr 拮抗剂的开发和合成、构效关系研究、这些分子的生物活性及其治疗潜力。